Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events
Item 8.01. Other Events.
On January9, 2019, Herriot Tabuteau, M.D., Chief Executive Officer of Axsome Therapeutics,Inc. (the “Company”), will present at the 11th Annual Biotech Showcase to provide an overview of the Company’s business and late-stage clinical product candidates. The materials to be used in connection with this presentation are filed as Exhibit99.1 hereto and are incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Corporate Presentation. |
Axsome Therapeutics, Inc. Exhibit
EX-99.1 2 a19-1343_2ex99d1.htm EX-99.1 Exhibit 99.1 NASDAQ: AXSM January 2019 © Axsome Therapeutics,…
To view the full exhibit click here
About Axsome Therapeutics,Inc. (NASDAQ:AXSM)
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).
